Reply from the board secretary of Hepuri: As of the end of 2021, the AR-301 global phase III clinical trial has enrolled 139 patients – yqqlm

  • Post date April 25, 2022 — 19:52 Post Lock Login to View

Key Data Concepts:   
? These are the company names, stock quotes, topics, and entities related to this data.

002399 002786 002913 300568 300760 Aoshikang Technology Shenzhen Hepalink Pharmaceutical Group Shenzhen Mindray Bio-Medical Electronics Shenzhen Senior Technology Material Shenzhen Silver Basis Technology Crime, Law, Justice Law Annual, Special Corporate Meeting Annual Report Research, Development Health, Beauty Product Financial, Business Service Credit, Debt Currency Market, Exchange Securities University Chemistry Scientific Research Athletics, Track, Field Economy, Business, Finance Health

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets


Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!


Already have an account?
Login



Related Data